🇺🇸United States·March 31, 2026·daily

US SEC Trading Suspension Halt Orders — March 31, 2026

Across four US exchange filings in the trading suspensions stream, a split emerges with two companies (Classover Holdings and USBC, Inc.) regaining compliance and two facing severe challenges (Iterum Therapeutics delisting and Snail, Inc. deficiency notice), highlighting volatility in micro-cap listing standards amid economic pressures. Key period-over-period trends show inconsistent profitability, exemplified by Snail's net income in 2024 contrasting losses in 2023 (-ve) and 2025 (-ve), signaling erratic financial health without YoY revenue or margin data available. Critical developments include Iterum's imminent Nasdaq delisting and suspension on April 1, 2026, due to bid price failure and Irish winding-up petition, posing total illiquidity risk, while compliance regains boost short-term stability for KIDZ and USBC. Portfolio-level patterns reveal 2/4 emerging growth companies navigating Nasdaq/NYSE American rules, with positive resolutions outpacing negatives but high materiality (avg 8.5/10) underscoring time-sensitive risks. Market implications favor short positions on delisting candidates and monitoring turnaround catalysts, as no insider activity or capital allocation shifts were noted across filings.

4 high priority4 total filings

🇺🇸United States·March 31, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 31, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (42 new), outright distress is limited to 2 Chapter 11/7 bankruptcies (Lipella Pharmaceuticals, IO Biotech), 1 Nasdaq delisting with Irish winding-up (Iterum Therapeutics), 1 Nasdaq deficiency notice (Snail Inc.), and 1 asset sale leading to dissolution (Allbirds), concentrated in small-cap biotechs signaling sector fragility amid cash burn. However, 25+ filings detail proactive refinancings, new credit facilities (e.g., Prologis $B-scale global credit, Ares 3-yr term loan, Lincoln National $2B revolver), and equity raises (e.g., Satellogic $50M ATM, SCYNEXIS $40M placement), indicating liquidity bolstering to avert distress rather than collapse. Period-over-period trends show mixed revenue performance: nCino +6% Q4/+10% FY revenues to $594.8M with GAAP profitability turn ($5.2M FY NI vs -$37.9M prior); Purple +9.1% Q4 rev but -3.9% FY to $468.7M, EBITDA to +$1.9M from -$20.8M. Forward-looking catalysts include Q2 2026 M&A closes (Repay-KUBRA $372M, Allbirds $39M sale), nCino FY2027 rev guidance $639-643M (+8% at midpoint), and biotech approvals (SCYNEXIS Phase 2 data). Portfolio-level patterns reveal financing optimism (positive sentiment 20/50) vs biotech risks (negative/mixed 8/50), with capital allocation favoring debt/equity over buybacks/dividends, creating opportunities in stabilized microcaps but high short-term volatility risks.

50 high priority50 total filings

🇺🇸United States·March 31, 2026·daily

US Executive Officer Management Changes SEC — March 31, 2026

Across 40 filings in the USA Executive & Director Changes stream (March 31, 2026), a dominant theme is leadership consolidation and transitions, with BlackRock appointing Jay Jacobs as President/CEO across 7 iShares ETF sponsors (Bitcoin, Silver, Gold Micro/IAU, Ethereum, Staked Ethereum, Commodity-Indexed Trusts), replacing Shannon Ghia without disputes, signaling centralized expertise amid crypto/commodity volatility. Positive appointments dominate (e.g., experienced execs at Immunic, Skillsoft, AlTi Global, Crown Holdings, Amrize), with 12/40 filings showing bullish sentiment tied to growth strategies, while neutral sentiment prevails in 25/40 and one negative (Rallybio CMO exit). Limited period-over-period data highlights T1 Energy's record Q4 2025 production (1.13 GW, +YoY sales $358.5M) and improved net loss (-$190M vs -$367M Q4 2024), maintaining 2026 guidance (3.1-4.2 GW); other trends include AlTi's $93B AUM and Amrize's $11.8B 2025 revenue. No widespread insider selling/buying noted, but capital allocation via bonuses (High Roller CEO $250K), severance (Eos, Bogota), and RSUs (HF Sinclair Acting CEO ~$105K) indicates retention focus. Portfolio implications: Stability in finance/biotech (e.g., First Foundation merger-ready exec fixes), but monitor successor gaps (Barinthus PAO, MSCI CAO) for operational risks; alpha in pre-catalyst firms like Immunic (Phase 3 data E2026).

40 high priority40 total filings

🇺🇸United States·March 31, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 31, 2026

Two biotech/pharma companies, Lipella Pharmaceuticals Inc. and IO Biotech, Inc., filed for bankruptcy within two days (March 30-31, 2026), signaling acute distress in the emerging growth biotech sector amid funding challenges and operational failures. Both filings carry maximal materiality (10/10) with uniformly negative sentiment, warning shareholders of highly speculative trading, substantial total loss risks, and no expected recoveries. No positive period-over-period trends evident; instead, implied severe deterioration led to Chapter 11 (Lipella, reorganization) and Chapter 7 (IO Biotech, liquidation) proceedings, with IO Biotech ceasing all operations, terminating staff/leadership, and defaulting on a €22.5M EIB loan. Key market implication: Nasdaq-listed IOBT and Lipella shares decouple from fundamentals, presenting extreme volatility and downside. Portfolio-level pattern: Cluster of insolvencies highlights biotech funding winter, with no capital allocation (dividends/buybacks), insider activity, or forward guidance beyond liquidation warnings.

2 high priority2 total filings

🇺🇸United States·March 31, 2026·daily

US Corporate Board Director Changes SEC Filings — March 31, 2026

Across 40 filings in the USA Board Room Changes stream (36 new), the dominant theme is executive and board transitions, with 22 appointments/promotions (e.g., experienced directors/CEOs in biotech, banking, wealth mgmt) and 18 resignations/retirements, 70% neutral sentiment, 25% positive, 5% negative/mixed. A cluster of 9 iShares ETF filings reveals BlackRock's uniform leadership shift appointing Jay Jacobs (ex-Global X ETFs, BlackRock equity ETFs head) as Sponsor CEO/President replacing Shannon Ghia across Gold, Bitcoin, Silver, Ethereum, etc., signaling consolidated ETF oversight amid crypto/commodity volatility. Financial trends limited but notable: T1 Energy improved Q4 2025 net loss 48% YoY ($367.2M to $190M), full-year loss narrowed 15% YoY, maintained 2026 production guidance 3.1-4.2 GW with $375-450M EBITDA run-rate 2027. Positive capital allocation in High Roller ($250k CEO bonus), T1 ($160M PTC sale at $0.91/watt), HF Sinclair (RSU grants to acting CEO); no broad insider trading but smooth successions imply management conviction. Portfolio-level: Banking/fintech shows merger-driven stability (First Foundation April 1 close), biotech adds commercialization expertise pre-catalysts (Immunic Phase 3 data E2026), overall bullish for growth sectors via expertise infusion but watch unnamed successors.

40 high priority40 total filings

🇺🇸United States·March 31, 2026·daily

US Merger & Acquisition SEC Filings — March 31, 2026

Across 10 US SEC filings focused on M&A and takeover activity in the period ending March 31, 2026, a surge in deal completions dominates, including 4 de-SPAC mergers/IPOs/amendments (Trailblazer/Cyabra, Soulpower, Spartacus, Inflection Point, Live Oak), 3 acquisitions (SCYNEXIS, Spire, Oramed/Lifeward), 2 divestitures (BrightSpring, Oramed), and 1 share authorization (Mobivity), signaling robust M&A momentum in biotech, utilities, health services, and SPACs. No explicit period-over-period financial declines reported; instead, themes of portfolio optimization via divestitures and bolt-on acquisitions highlight strategic refocusing without margin compression or YoY revenue drops noted. SPAC activity is particularly hot with 5 filings, pro forma valuations up to $8.5B (Soulpower), and trading commencements imminent. Positive sentiment prevails in 7/10 filings (avg materiality 8.5/10), with forward-looking catalysts like Phase 2 trials (SCYNEXIS Q4 2026) and EPS growth targets (Spire 5-7%). Mixed/neutral tones in Soulpower (closing delay), Live Oak, and Mobivity flag execution risks. Implications: Investors should prioritize post-deal liquidity events and pipeline readouts for alpha, as capital allocation favors growth via M&A over buybacks/dividends.

10 high priority10 total filings

🇺🇸United States·March 31, 2026·monthly

US Pre-Market SEC Filings Roundup — March 31, 2026

Across 50 overnight SEC filings, mixed sentiment dominates with 14 mixed, 9 positive, 5 negative, and 22 neutral, reflecting resilient capital allocation amid uneven operational trends; energy firms like AleAnna and Dawson show strong YoY EBITDA growth (AleAnna $6.6M FY, Dawson +139% to $4.7M) offset by renewable losses and flat margins, while biotechs (Aktis, DiaMedica, OS Therapies) report clinical progress but widening net losses (OS +224% to $28.8M). Financials and REITs emphasize shareholder returns via buybacks (First Northern 6% of shares ~$15.6M, News Corp $1B program) and dividends (SmartStop $1.60 annualized, AGL $0.60/share), alongside credit expansions (Prologis global facility, Ares 3-year term loan). M&A activity surges in defense/tech (Red Cat $25M Quaze + Apium acquisitions) and resources (Range Impact coal mines boosting assets 20x to $123M), but SPACs and crypto (Solana $40.9M FY loss despite $325M Q4 net income) highlight volatility. Portfolio-level trends include 7/15 reporting entities with revenue growth >20% YoY (e.g., Dawson Q4 +67%), but 6/12 with margin stability or compression; activist push at Lululemon (8.6% stake, proxy fight) signals governance risks. Key implications: Favor buyback-heavy financials and acquisition-driven small caps pre-market, monitor biotech catalysts into mid-2026.

33 high priority17 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Technology Sector SEC Filings — March 30, 2026

Across 17 filings from the USA S&P 500 Technology stream, overarching themes include mixed financial recoveries with revenue growth in 5/10 10-K filers (avg +55% YoY in reporters like Inmune Bio +257%, CareView +9%) but persistent net losses narrowing avg 40% YoY, impairments dragging results (ImmuCell $2.7M, Inmune $16.5M), and Nasdaq compliance risks in biotech-adjacent plays. Capital allocation leans shareholder-friendly with repurchases (Cottonwood 1.37M shares, Atmus $61M) and dividends (Sun Communities increases), while M&A pursuits (AParadise-Enhanced Ltd, Atmus-Koch $1.5B) signal growth ambitions amid activist pressures (Weave). Portfolio-level trends show gross margin expansion in 4/7 reporters (avg +25%, ImmuCell +44%) offset by G&A rises and cash burns, with positive operating cash in ImmuCell (+592% YoY) and CareView turnaround. Critical developments: Nasdaq delist threats (Dyadic dual notices), proxy solicitations (Genco, Sun), and May 2026 catalyst cluster (meetings, compliance plans) imply near-term volatility. Market implications favor monitoring turnarounds with improving ops cash but flag liquidity strains in cash-poor entities (SportsQuest $259 cash).

13 high priority4 medium17 total filings

🇺🇸United States·March 30, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 30, 2026

Across 21 NASDAQ-100 related filings from March 30, 2026, overarching themes include mixed financial turnarounds in small-cap biotech and tech firms with revenue softness offset by margin improvements and positive cash flows (e.g., ImmuCell gross profit +44% YoY, CareView operating cash +$805K), contrasted by Nasdaq delisting risks and impairments; period-over-period trends show 6/15 annual reports with revenue growth averaging +9% YoY (CareView +9%, ImmuCell +4%) but 4 with declines averaging -9% (Intellinetics -8%), alongside net loss improvements in 5 cases (ImmuCell -52%). Positive governance events dominate large caps like Starbucks (98% director support) and Atmus (EBITDA +7.3% YoY, $1.5B acquisition), with capital returns via repurchases (Cottonwood 1.37M shares, Atmus $61M) and debt management (Sun $3B paydown). Biotech highlights clinical progress (PepGen Phase 2 data), while shipping faces oversupply risks; portfolio-level patterns signal selective small-cap alpha from operational pivots amid activist interventions (Weave) and liquidity boosts (Mueller $100M facility), but flag microcap distress (Dyadic deficiency). Market implications favor monitoring May catalysts for compliance and M&A, with relative outperformance in SaaS/software segments.

13 high priority8 medium21 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Financials Sector SEC Filings — March 30, 2026

Across 50 SEC filings from diverse S&P 500-adjacent names (heavy biotech/energy tilt despite Financials stream), overarching themes include prolific equity capital raises exceeding $2.5B (e.g., OnKure $150M, Capstone $112.5M, Aprea $30M) funding pipelines/growth but risking dilution; M&A surge with $30B+ EV (Sysco/Jet ro $29.1B, Boston Sci/Penumbra, Affinity $142.8M); mixed FY2025 results in 25/50 with revenue (12 up avg +60% YoY like CBAK Q4 +132%, Fathom +25%; 13 down avg -20% like Soluna -22%, Socket -20%) and gross margins compressing avg -350bps in decliners (CBAK 9.4% vs 23.7%). Losses narrowed in 10 biotechs (avg -40% YoY, e.g., Unicycive -30%, OneMedNet -72%) via R&D cuts but widened in 8 (avg +50%). Forward catalysts cluster in May-Jun 2026 (merger votes, AGMs, PDUFA); capital allocation favors reinvestment over returns (Conoco $9B buybacks/divs outlier). Implications: alpha in accretive M&A/biotech catalysts, caution on dilution/margin squeezes; portfolio trend toward defensive M&A plays amid volatile growth.

27 high priority23 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (despite diverse tickers including biotechs, energy, and SPACs), mixed sentiment dominates (14/50 mixed), with revenue declines averaging ~10% YoY in 18 reporting companies (e.g., ARKO -12.3%, Intellinetics -8%, Sangamo -32%), offset by cost reductions narrowing net losses in 9/22 loss-reporting firms (e.g., Neumora -3% FY loss, ImmuCell -52%). Biotech/pharma filings (10+) highlight pipeline catalysts clustered in Q2-H2 2026, while energy/utilities show debt optimizations (Atmos extensions, Electra liabilities -44-99%). Capital allocation leans conservative with sparse dividends (ARKO $0.26/share, Brookfield $0.07/share) and no buybacks noted; cash runway extensions into 2027 common amid high burn. Portfolio-level trends reveal margin expansion in 7/15 (e.g., ImmuCell +44% gross profit) despite volume pressures, signaling operational resilience but macro headwinds. M&A/divestitures active (CVD SDC sale $16.9M Q2 2026 close, KEEMO control change), with AGMs/earnings imminent. Implications: Selective opportunities in catalysts and turnarounds, caution on cash burns and rev softness.

31 high priority19 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (including adjacents like energy and materials), FY2025 results reveal mixed performance with standout revenue accelerations in niche growth areas (e.g., CBAK Energy Q4 +131.8% YoY to $58.8M driven by LEV +524%, Legence +21.5% to $2.55B fueled by data centers +50.1%) offset by widespread margin compressions (e.g., CBAK FY gross margin -1430bps to 9.4%) and net losses (12/20 10-Ks reported wider losses YoY). Refinancings strengthened balance sheets (Ingevity $750M rev facility, MediaAlpha $150M term loan), while M&A activity (Addentax 62% stake in Keemo Fashion, Hecla Quebec sale) and capital returns ($9B ConocoPhillips buybacks/dividends) signal confidence. Proxies (Baker Hughes, Conoco, S&T Bancorp) show low insider ownership (<1%) and standard governance with ownership guideline hikes. Forward catalysts include mid-2026 clinical readouts (Reviva Phase 3, Connect Biopharma Phase 2), April-May shareholder meetings, and AAN poster (AEON April 2026). Portfolio implications: Bullish on data/energy efficiency plays amid margin pressures; monitor going concern risks in biotechs (Reviva, Genprex, CISO). Actionable now: Favor refinanced industrials over loss-makers.

28 high priority22 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Energy Sector SEC Filings — March 30, 2026

The S&P 500 Energy stream reveals proxy season kicking off with 10+ AGMs clustered in May 2026, highlighting strong 2025 performance at key players like ConocoPhillips (2,375 MBOED production, $19.8B cash ops, $9B shareholder returns including $5B buybacks/$4B dividends, 15% YoY Lower 48 drilling efficiency gains, $1B Marathon synergies). Devon Energy's proposed Q2 2026 merger with Coterra (mixed sentiment due to risks/no appraisal rights) signals consolidation amid neutral-to-positive sentiment overall. Portfolio-level trends show robust capital returns and operational efficiencies in upstream (COP) contrasting neutral governance disclosures elsewhere; COPT Defense (non-core but contextual) boasts 95% leased rates and exceeded 2025 scorecard (except one metric). No widespread margin compression or declines noted, with forward catalysts centered on virtual AGMs (May 12-21) and merger close. Baker Hughes discloses low insider ownership (<1%) and strict no-pledge policies. Mixed signals from non-energy filings (e.g., AParadise unproven DTC platform, Neogen exec departure) underscore energy focus purity but highlight M&A risks.

7 high priority5 medium12 total filings

🇺🇸United States·March 30, 2026·daily

US Material Events SEC 8-K Filings — March 30, 2026

Across 50 8-K filings from March 30, 2026, the dominant theme is aggressive capital structure optimization through refinancings, new credit facilities, and note issuances (e.g., Ingevity's $750M revolver, Nexstar's $1.75B Term B-7, MediaAlpha's $150M term/$60M rev), enhancing liquidity without reported performance declines. Strategic M&A and divestitures highlight focus on core operations (Leidos $2.4B ENTRUST acquisition doubling energy exposure; Spire $215M gas marketing sale; Compass $292.5M Sterno divestiture reducing leverage below 1.0x). Biotech sector shows robust funding and milestones (OnKure $150M raise for PI3Kα inhibitors with H1 2027 INDs; Connect Biopharma positive Phase 1 FEV1 improvements ~200-400mL, Phase 2 mid-2026; Aprea $30M for ACESOT-1051 expansion to Q1 2028 runway). Limited period-over-period data reveals mixed guidance (Spire affirms FY2026 $5.25–$5.45 EPS but cuts FY2027 to $5.40–$5.60 from $5.65–$5.85); Inogen reaffirms Q1/FY2026 outlook post positive EBITDA turn. Board changes are prevalent (50% of filings), mostly neutral appointments/resignations, with rare discord (Ensysce director exit over severance). No broad insider trading patterns, but capital allocation leans toward deleveraging and growth reinvestment over dividends/buybacks. Overall, positive sentiment in 40% of filings signals resilience, with opportunities in energy/utilities and biotech amid neutral/mixed financing dilution risks.

50 high priority50 total filings

🇺🇸United States·March 30, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 30, 2026

Across the 50 filings in the USA Dow Jones 30 intelligence stream (primarily small/mid-cap proxies but including DJ30 names like Boeing and Baker Hughes), sentiment is mixed with 14 positive, 18 mixed, and 12 neutral/negative, reflecting resilient capital raises and M&A amid revenue volatility. Period-over-period trends show revenue growth in 8/22 reporting companies (avg +72% YoY where positive, e.g., CBAK Q4 +131.8%, Global Arena Q1 +72%), but declines in 14 (avg -15%, e.g., Soluna FY2025 -22%, ARKO -12.3%), with gross margins compressing broadly (avg -300bps in mixed reporters like CBAK 23.7% to 9.4%). Biotech firms dominate positive catalysts, narrowing net losses (avg -25%, e.g., Unicycive -28%, Reviva -33%) ahead of FDA milestones, while SPACs advance mergers (Vine Hill 92.6% approval). Capital allocation leans toward equity/debt raises ($142M Soluna, $112.5M Capstone) over dividends/buybacks (none noted), signaling growth focus but dilution risks. M&A completions (Leidos $2.4B, CVD SDC $16.9M) and credit amendments (Ingevity $750M revolver) highlight deal momentum, with DJ30 filings mostly neutral proxy boilerplate. Portfolio implication: Opportunistic buys in biotech/SPAC catalysts, caution on revenue-dependent industrials amid margin pressure.

37 high priority13 medium50 total filings

🇺🇸United States·March 30, 2026·daily

US SEC Filings Daily Market Digest — March 30, 2026

Across 50 SEC filings for March 30, 2026, 10-Ks reveal polarized financial trends with 12/22 reporting revenue growth (avg +85% YoY in winners like General Enterprise Ventures +195%, Embraer +18.5%) but 15 showing widening net losses (avg +150% YoY, e.g., Picard Medical +28%, Origin Materials +198%) amid impairments and high expenses; SPACs (9 filings) universally report no revenue, mounting deficits (avg -$500K), and going concern doubts. Biotech/pharma shines with Alumis' Phase 3 psoriasis trial success and OnKure's $150M raise for PI3K inhibitors, contrasting Dyadic's Nasdaq equity deficiency. Capital allocation favors buybacks (News Corp $1B program, ConocoPhillips $5B in 2025) and financings ($119M Soluna cash surge), while M&A/strategic deals (RYVYL $10M deposit acquisition, Contango exchangeables) signal consolidation. Energy (Conoco, Endeavour) shows resilience with production gains and audit stability, but REITs/CRE (Presidio, CIM) face NOI pressures yet NAV stability. Forward catalysts cluster in H2 2026 (NDAs, pilots) with May 12 AGMs for Conoco/Accelerant; overall, selective bullish signals in biotech/energy amid broad microcap risks, favoring nimble portfolios.

38 high priority12 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, entertainment, and adjacent sectors), sentiment is predominantly mixed (14/50), with positive operational milestones (e.g., Sable Offshore oil resumption, Fermi $1.8B raised) offset by financial pressures like revenue declines (Helio -65% YoY), margin compressions (banks avg NIM down ~40bps), and impairments (Falcon's $8.3M). Key period-over-period trends show revenue growth in 12 firms averaging +45% YoY (outliers: Fathom +25%, Falcon's +121%), but net losses persisted or widened in 18 cases; gross margins expanded in retail (Lulus +640bps Q4) while compressing in finance/REITs (avg -150bps). Capital allocation favors dividends/special payouts (Sanfilippo $1.50, Blue Ridge $0.60, Brookfield $0.0721) over buybacks, with M&A/divestitures prominent ($142.8M Affinity merger, $292.5M Compass sale). Portfolio-level patterns indicate turnaround potential in retail/entertainment amid consumer softness, but risks from NPAs rising 200%+ in banks and ongoing deficits (Pacific Coast). Critical implications: near-term catalysts from Q2'26 AGMs/mergers offer arb plays; monitor deleveraging post-asset sales for alpha.

25 high priority25 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 30, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (primarily biotech, pharma, med devices amid broader financials), dominant themes include robust M&A activity (BSX-Penumbra merger, Aurinia-Kezar acquisition) and FDA catalysts (Unicycive OLC PDUFA June 29, 2026), with mixed FY2025 financials showing 6/10 biotechs narrowing net losses YoY (avg -25%, e.g., Unicycive -28% to $26.6M) but rising G&A/R&D expenses averaging +40%. Period-over-period trends reveal healthcare innovators extending cash runways into 2027 (Unicycive $54.9M, Aura $144.2M) despite no revenues, contrasting with deteriorations like Ensysce net loss widening 28% to $10.2M and Interpace PancraGEN discontinuation post-CMS loss. Capital allocation leans toward equity raises (Artelo $11M private placement) and buybacks (News Corp $1B program), while non-healthcare filings (e.g., CIM REIT portfolio -1.6% YoY) dilute focus but highlight relative biotech resilience. Critical developments like Sight Sciences $34M patent win and ProCap merger approval signal upside, but risks from delistings (Interpace, Zivo) and going concerns (CISO) warrant caution. Portfolio-level, healthcare shows +9% avg revenue growth in reporting firms (CareView +9%) with margin stabilization, positioning for H2 2026 catalysts amid sector M&A premiums.

29 high priority19 medium48 total filings

🇺🇸United States·March 30, 2026·daily

US Executive Compensation Proxy SEC Filings — March 30, 2026

Across 34 DEF 14A proxy statements filed around March 30, 2026, a dominant theme is robust 2025 performance with 12 companies reporting double-digit revenue growth (avg 10% YoY, e.g., Frontdoor +14%, KBR +11%) and 8 highlighting EBITDA expansions (avg +12% YoY), contrasted by mixed signals from leadership transitions in 7 firms and disruptions like merger terminations. Capital allocation trends show aggressive shareholder returns with $3B+ debt paydown (Sun Communities), $5B buybacks (ConocoPhillips), and dividend hikes in 6 companies (avg +12%, e.g., Patrick +17.5%), signaling financial health amid governance focus via high Say-on-Pay support (avg 96% where reported). Biotech/pharma firms (Tonix, Onconetix, Auddia, Atossa, XOMA) cluster reverse stock split proposals, indicating compliance risks, while energy/industrials (Conoco, KBR, Xylem) lead positive sentiment (9/10 positive filings). Portfolio-level, margins expanded in 6/10 with operational metrics (e.g., Conoco 15% drilling efficiency gain), but CEO changes (Rayonier, Fortune Brands, Pitney Bowes) and SPAC extensions (GP-Act III) flag caution. May 2026 annual meetings form a dense catalyst calendar (25+ events), with declassification votes and comp approvals as key votes. Implications favor cyclicals with buybacks over speculative biotechs.

34 high priority34 total filings

🇺🇸United States·March 30, 2026·daily

US IPO Pipeline SEC S-1 Filings — March 30, 2026

The IPO Pipeline stream features two SEC filings on March 30, 2026: Cadre Holdings' S-4 shelf registration for up to 7,500,000 shares to fund future acquisitions and Elmet Group Co.'s S-1 for its initial public offering on Nasdaq under 'ELMT'. No period-over-period financial comparisons are available, as Elmet's preliminary prospectus explicitly provides no financial performance data and Cadre's filing focuses on share registration without operational metrics. Neutral sentiment prevails across both, with Elmet carrying higher materiality (10/10) due to its IPO status as an emerging growth and smaller reporting company in fabricated metal products. Cadre signals proactive M&A strategy in safety equipment markets, while Elmet highlights speculative high-risk entry into public markets post-reorganization on January 2, 2026. Portfolio-level pattern: Early-stage capital market preparations amid neutral outlook, with no YoY/QoQ trends but potential for new listings and dilution. Market implications include monitoring for IPO catalysts and acquisition targets, positioning investors for alpha in industrials.

2 high priority2 total filings